Other Therapies
TPPE – Therapeutic Partial Plasma Exchange
AVAILABLE
Therapeutic Partial Plasma Exchange is an advanced version of TPE (Therapeutic Plasma Exchange) which our medical team uses in combination with H.E.L.P. Apheresis due to the significantly better risk-benefit profile in chronic illness. This therapy is not used for patients suffering from fatigue/PEM. For some of those patients it is used later on in the therapy course (when the fatigue/PEM has subsided already).
Careful – do not mix up TPPE with TPE that does not show results in Long Covid: https://www.nature.com/articles/s41467-025-57198-7.pdf
Therapeutic Plasma Exchange (TPE) with albumin (artificial plasma) can have severe side effects for people with chronic illness. This is why we developed a much ‘softer’ version (Therapeutic Partial Plasma Exchange) where only a small fraction of the plasma is exchanged at the end of a H.E.L.P. Apheresis therapy with saline (NaCl. 0,9%). In other words – it increases the efficiency of the original H.E.L.P. Apheresis by removing an even higher percentage of autoantibodies and pathogens, but as it also removes a small fraction of the plasma, which is why it can not be used for fatigue/PEM patients.
Side effects if removal/administration ratio and timing are handled wrong include swollen ankles and facial oedemas.
You will find extensive information on our blog post about different types of Apheresis and which type is suitable for which purpose HERE
Chelation Therapy
AVAILABLE
Chelation therapy, from a scientific standpoint, revolves around the administration of chelating agents, which are organic compounds capable of forming stable bonds with metal ions. The chelation process involves the formation of coordination complexes, where the chelating agent encircles the target metal, creating a ring-like structure. Ethylenediaminetetraacetic acid (EDTA) is a commonly employed chelating agent in clinical settings. In the context of heavy metal toxicity, chelation therapy operates by facilitating the removal of toxic metals from the body through the formation of water-soluble chelates that can be excreted via urine. Beyond its established utility in heavy metal detoxification, chelation therapy has been explored for its potential cardiovascular benefits. The hypothesis posits that chelation may mitigate atherosclerosis by binding to and removing calcium deposits within arterial walls.
*service supplied by Akamantis Health
LDN (Low Dose Naltrexone) Therapy
AVAILABLE
LDN shows benefits for fatigue patients.
Here you find a related research article.
Methylene Blue & Red Light Therapy
AVAILABLE
Stellate Ganglion Block
AVAILABLE
Stellate ganglion block (SGB) – single- or doublesided injection of anesthetic medication into a collection of nerves called the stellate ganglion.
Many patients experienced an alleviation of dysautonomia symptoms following a stellate ganglion block.
Other symptoms that improved or resolved were: anxiety/PTSD, arosmia and parosmia. The positive effects of a stellate ganglion block can sometimes last, but often are temporary (which is fine as it gives the body a ‘time-out’ to regenerate).
Also available via radiofrequency ablation instead of anesthetic medication.
*service supplied by Dr. Periklis Zavridis
Magnesium Oxygen Therapy
AVAILABLE
Prof. Elfriede Leniger-Follert was the head of a research group at the Max Planck Institute at the Institute of Systems Physiology that focussed on the oxygen supply to the brain.
Her discovery at the time was that magnesium could help to widen constricted microvessels again and normalise the oxygen supply. She discovered this mechanism of the disease-related narrowing of the microvessels in 1983. This reduces the oxygen supply to the brain, the retina, the inner ear, the lungs and liver, the kidneys and the feet.
In all circulatory disorders, the outer side of the vascular muscle cells is negatively charged compared to the positively charged inner side (potassium depolarisation). This reversal is the trigger for the shortening of the ring-shaped vascular muscles, which thus become narrower.
A few years later, she discovered that magnesium ions are capable of reversing the unfavourable charge distribution. This opens and widens the blood vessels again.
Prof. Leniger-Follert uses direct IV injections into the veins and oxygen concentrators directly after.
We have developed a similar therapy based on the decade long knowledge of our medical team and have adapted her findings to the use with Hyperbaric Oxygen combined with IV treatment with Magnesium NaCl solution.
Magnesium Oxygen Therapy – but literally supercharged.
Cryotherapy
AVAILABLE
The principle behind cryotherapy lies in its ability to trigger beneficial responses within the body, such as vasoconstriction and the release of anti-inflammatory molecules. As the cryogenic temperatures envelop the body, they prompt a cascade of reactions that can potentially alleviate symptoms, enhance circulation, and promote overall well-being.
Current studies can be found here:
POST-COVID SYMPTOMS AND WHOLE-BODY CRYOTHERAPHY: A CASE REPORT
Whole Body Cryotherapy for Long COVID Brain Fog
*service supplied by Panacea Medical Center
B-Cell Depletion Therapy
AVAILABLE
(Use case: In case of high autoantibody levels, after IVIG Therapy.)
Complement System Therapy
UNDER EVALUATION – RESEARCH ONGOING
(Side effects unknown, insufficient clinical evidence for targeted off-label use.)
Complement inhibitors are administered as subcutaneous infusions, intravenous infusions or oral capsules.
Here is a list of some well-known complement inhibitors (source: RXList):
- Evacopan
- Eculizumab
- Empaveli
- Enjaymo
- Gohibic
- Pegcetacoplan
- Pozelimab
- Pozelimab-bbfg
- Ravulizumab
- Ravulizumab-cwvz
- Soliris
- Sutimlimab
- Sutimlimab-jome
- Tavneos
- Ultomiris
- Veopoz
- Zilucoplan
We recommend to read the following study for a better understanding of the cell damages that seem to be caused in a large group of Long Covid patients by the complement system: https://www.usz.ch/en/complement-system-causes-cell-damage-in-long-covid/
Anecdotal note: The Complement System seems to return to its normal state after H.E.L.P. Apheresis treatments / Combination Therapy in most patients. Single healing attempts with off-label use of complement system inhibitors are not very common yet and there is little known about the efficiency of the various existing inhibitors in Long Covid.
*Despite emergency use authorisation of certain complement inhibitors for COVID-19, Complement System Treatment will first be available when sufficient clinical evidence is collected for targeted off-label use. One thing to consider is the numerous side-effects of the various complement inhibitors.
Why do we publish this information? We get many enquiries regarding Complement Treatment and want to share what is known so far.
IMPORTANT NOTE: Rituximab and Obinutuzumab despite very similar sounding names are NOT complement inhibitors – they are mABs complement activators and important for B-Cell depletion therapy (which has been mainly researched for multiple sclerosis but is now subject of research in other chronic conditions too)
